Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Armata Pharmaceuticals Inc (ARMP)

$6.35 -0.33 (-4.94%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	243.20M
Revenue (ttm)	5.17M
Net Income (ttm)	-18.92M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-365.96%
Debt to Equity Ratio	-1.53

Volume	198,900
Avg Vol	70,352
Day's Range	N/A - N/A
Shares Out	36.41M
Stochastic %K	25%
Beta	1.29
Analysts	Strong Sell
Price Target	$12.00

Company Profile

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement...

Industry: Biotechnology

Sector: Healthcare

Phone: 310 665 2928

Fax: 310 665 2963

Website: www.armatapharma.com

Address:

5005 McConnell Avenue, Los Angeles, United States

King_of_the_bagholders Jan. 14 at 12:13 PM

$ARMP

0 · Reply

Silmarjhg Jan. 13 at 6:32 PM

$ARMP microcap energy, float can snap, watch for volume ignition and a clean breakout hold

0 · Reply

Trapped Jan. 13 at 4:09 PM

$ARMP good news , best news. stock goes down…wtf

0 · Reply

Almas2025 Jan. 13 at 3:07 PM

$ARMP worst company never buy!

0 · Reply

King_of_the_bagholders Jan. 13 at 1:47 PM

$ARMP unbelievable how quiet it is in here given the news. Better early than late I suppose. I’ll reshare this later after we gain 5k in followers today.

0 · Reply

OpenOutcrier Jan. 13 at 1:35 PM

$ARMP (+1.8% pre) Antibiotic-resistant Staphylococcus aureus study moves to Armata Phase 3 https://ooc.bz/l/89523

0 · Reply

King_of_the_bagholders Jan. 13 at 1:32 PM

Today’s plays $ARMP $ATON $NVO Do your own DD 😉

0 · Reply

briefingcom Jan. 13 at 1:11 PM

$ARMP: Armata Pharmaceuticals (+2.7%) announces end-of-phase 2 meeting with FDA and plans to advance AP-SA02 to a phase 3 superiority study in complicated bacteremiastaphylococcusaureus

0 · Reply

Soyaz Jan. 13 at 12:45 PM

$EVTV $ATON Also $ARMP may run...moves quick

0 · Reply

Aburose Jan. 13 at 12:31 PM

$ARMP let see this trash if it can moves

1 · Reply

Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus

Nov 18, 2025, 7:00 AM EST - 2 months ago

Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST

Nov 12, 2025, 4:05 PM EST - 2 months ago

Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update

Nov 10, 2025, 7:00 AM EST - 2 months ago

Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California

Oct 22, 2025, 11:10 AM EDT - 2 months ago

Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™

Oct 14, 2025, 7:00 AM EDT - 3 months ago

Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™

Sep 8, 2025, 7:00 AM EDT - 4 months ago

Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology

Sep 4, 2025, 7:00 AM EDT - 4 months ago

Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 4:05 PM EDT - 5 months ago

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

May 19, 2025, 7:00 AM EDT - 8 months ago

Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia

May 14, 2025, 4:05 PM EDT - 8 months ago

Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update

May 1, 2025, 7:00 AM EDT - 9 months ago

Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Mar 20, 2025, 5:56 PM EDT - 10 months ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update

Mar 12, 2025, 5:08 PM EDT - 10 months ago

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

INVA

Mar 11, 2025, 7:00 AM EDT - 11 months ago

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit

Dec 19, 2024, 7:00 AM EST - 1 year ago

Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Nov 19, 2024, 7:00 AM EST - 1 year ago

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting

Nov 13, 2024, 4:05 PM EST - 1 year ago

Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update

Nov 12, 2024, 7:00 AM EST - 1 year ago

Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia

Oct 30, 2024, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Announces Structural Biology Publication

Sep 5, 2024, 7:30 AM EDT - 1 year ago

Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 26, 2024, 7:30 AM EDT - 1 year ago

Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium

Aug 15, 2024, 4:45 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Jul 11, 2024, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Jul 10, 2024, 4:05 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024

May 7, 2024, 4:01 PM EDT - 1 year ago

Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update

Mar 21, 2024, 4:05 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update

Mar 4, 2024, 4:01 PM EST - 2 years ago

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

INVA

Feb 21, 2024, 7:00 AM EST - 2 years ago

Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit

Nov 14, 2023, 4:00 PM EST - 2 years ago

Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update

Oct 30, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference

Oct 19, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus

Sep 21, 2023, 7:00 AM EDT - 2 years ago

Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update

May 31, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy

May 11, 2023, 4:05 PM EDT - 2 years ago

Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update

Mar 16, 2023, 4:10 PM EDT - 3 years ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update

Mar 6, 2023, 6:00 AM EST - 3 years ago

Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis

Jan 10, 2023, 4:05 PM EST - 3 years ago

Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC

INVA

Dec 22, 2022, 8:00 AM EST - 3 years ago

Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Nov 28, 2022, 8:00 AM EST - 3 years ago

Armata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage

Nov 9, 2022, 4:15 PM EST - 3 years ago

Armata Pharmaceuticals Announces Third Quarter 2022 Results and Provides Corporate Update

Aug 11, 2022, 4:05 PM EDT - 3 years ago

Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update

Aug 1, 2022, 8:00 AM EDT - 3 years ago

Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections

May 23, 2022, 8:00 AM EDT - 3 years ago

Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia due to Staphylococcus aureus

May 12, 2022, 4:17 PM EDT - 3 years ago

Armata Pharmaceuticals Announces First Quarter 2022 Results and Provides Corporate Update

Mar 31, 2022, 4:05 PM EDT - 4 years ago

Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $45 Million Private Placement with Innoviva

INVA

King_of_the_bagholders Jan. 14 at 12:13 PM

$ARMP

0 · Reply

Silmarjhg Jan. 13 at 6:32 PM

$ARMP microcap energy, float can snap, watch for volume ignition and a clean breakout hold

0 · Reply

Trapped Jan. 13 at 4:09 PM

$ARMP good news , best news. stock goes down…wtf

0 · Reply

Almas2025 Jan. 13 at 3:07 PM

$ARMP worst company never buy!

0 · Reply

King_of_the_bagholders Jan. 13 at 1:47 PM

$ARMP unbelievable how quiet it is in here given the news. Better early than late I suppose. I’ll reshare this later after we gain 5k in followers today.

0 · Reply

OpenOutcrier Jan. 13 at 1:35 PM

$ARMP (+1.8% pre) Antibiotic-resistant Staphylococcus aureus study moves to Armata Phase 3 https://ooc.bz/l/89523

0 · Reply

King_of_the_bagholders Jan. 13 at 1:32 PM

Today’s plays $ARMP $ATON $NVO Do your own DD 😉

0 · Reply

briefingcom Jan. 13 at 1:11 PM

$ARMP: Armata Pharmaceuticals (+2.7%) announces end-of-phase 2 meeting with FDA and plans to advance AP-SA02 to a phase 3 superiority study in complicated bacteremiastaphylococcusaureus

0 · Reply

Soyaz Jan. 13 at 12:45 PM

$EVTV $ATON Also $ARMP may run...moves quick

0 · Reply

Aburose Jan. 13 at 12:31 PM

$ARMP let see this trash if it can moves

1 · Reply

King_of_the_bagholders Jan. 13 at 12:26 PM

$ARMP Jesus some actual volume?

0 · Reply

Aburose Jan. 13 at 12:25 PM

$ARMP Armata Pharmaceuticals Announces End-of-Phase 2 Meeting With FDA; FDA Agreed That Data From Phase 2a diSArm Study Support Advancement Of P-SA02 To Phase 3

0 · Reply

Aburose Jan. 13 at 12:24 PM

$ARMP 30 coming

0 · Reply

King_of_the_bagholders Jan. 13 at 12:11 PM

$ARMP MMs got no balls. Run this to 20 already

0 · Reply

Alex036 Jan. 12 at 6:03 PM

$ARMP Insiders have 70%. Who do you think controls all the SP movements here?

0 · Reply

Trapped Jan. 12 at 5:49 PM

$ARMP we need volume. undervalued here.

0 · Reply

King_of_the_bagholders Jan. 12 at 3:32 PM

$ARMP well this is boring… That options spread across the board is bananas. Some whale needs to push this to force a squeeze. Some greedy MM is holding all the cards

0 · Reply

Alex036 Jan. 9 at 8:20 PM

$ARMP $1 sounds not bad, but 12.67% sounds much worse. This company is not for sale.They have other goals.That is pretty obvious.

0 · Reply

Trapped Jan. 9 at 7:32 PM

$ARMP 42k shares traded. stock drop $1. just MMs looking for a buyer. has no reflection of company worth.

0 · Reply

Alex036 Jan. 9 at 6:33 PM

$ARMP Such a strange way to $15 :)

0 · Reply

Trapped Jan. 8 at 9:07 PM

$ARMP it’s a wall street gem. my guess we see $50 after $15 hits. no stops on the way. pure gold here

0 · Reply

King_of_the_bagholders Jan. 8 at 5:35 PM

$ARMP why hello again you sexy bitch

0 · Reply

1.0.0